Abstract
Immune checkpoint inhibitors (ICIs) targeting PD-L1 immunotherapy are state-of-the-art treatments for ad-vanced non-small cell lung cancer (NSCLC). Ho......
小提示:本篇文献需要登录阅读全文,点击跳转登录